All News

SAN FRANCISCO-Although there are many good metaanalyses, derived from combining the results of numerous solid clinical trials, there are also many “filled with garbage,” Deborah Grady, MD, said at the Seventh Symposium on Clinical Trials: Design, Methods and Controversies. It is incumbent on the physician to be able to distinguish the good from the bad, said Dr. Grady, associate professor of epidemiology, biostatistics and medicine, University of California, San Francisco (UCSF).

Developing and implementing cancer outreach programs for African-Americans takes planning and sensitivity, said Robin L.

Allen Lichter, MD, president of the American Society of Clinical Oncology (ASCO), stated at a meeting sponsored by the

COLUMBUS, Ohio-Hearing the words, “You have cancer,” is immediately upsetting. “That distress can echo through the years, negatively affecting a person’s quality of life [QOL] long after the initial diagnosis of cancer,” said Betty R. Ferrell, PhD, RN, research scientist, City of Hope National Medical Center. She spoke at a conference on cancer survi-vorship sponsored by the James Cancer Hospital and Solove Research Institute at Ohio State University. Indeed, she said, in a survey of cancer survivors, distress over initial diagnosis was ranked as the single most negative influence on quality of life, worse than fear of recurrent cancer, fear of cancer spreading, or physical symptoms like fatigue.

ALEXANDRIA, Va-Treating a patient in a clinical trial-nearly always a cancer patient’s best treatment option-is no more costly and far more effective than giving supposedly less expensive “established” care, reported William P.Peters, MD, PhD, president, director, and chief executive officer of the Barbara Ann Karmanos Cancer Institute, Detroit. Dr. Peters discussed a series of cost and outcome studies that reached this conclusion at the Annual Meeting of the Association of Community Cancer Centers.

MIAMI BEACH, Fla-The development of chemotherapy agents peaked between 1985 and 1990, Dr. Eric Rowinsky said at the annual meeting of the Network of Oncology Communication and Research (NOCR). “However, we saw the same types of drugs being developed (analogs of the platinums and anthracyclines) because we were using the same old screening system,” he said.

Viruses, such as the human immunodeficiency virus (HIV), are parasites: to reproduce, they need to appropriate their host’s

ALEXANDRIA, Va-Although physicians and other health professionals are not taught how to create or pass legislation, it is vital “for each of us to be involved in the legislative process,” Edward L. Braud, MD, said at the 25th Annual Meeting of the Association of Community Cancer Centers (ACCC).

ALEXANDRIA, Virginia-Genetic alterations very early in the disease process lie at the root of every cancer. Functional genomics, the study of which genes are actually functioning at a given time or stage, affords a “new approach” to fighting cancer, reported Kristina Cole, MD, PhD, a cancer research training fellow at the National Cancer Institute, Bethesda, Maryland.

ALEXANDRIA, Va-With 56% of cancer patients now receiving off-label therapies and “more than 50%” of physicians reporting problems getting reimbursement for these treatments, assuring coverage for such medications is a major focus of the Association of Community Cancer Centers’ legislative efforts at the state level, said Christian Downs, MHA, director of Provider Economics and Public Policy for the ACCC.

ALEXANDRIA, Va-Although nurses traditionally have not been sued individually for malpractice, changes in technology, medical practice, and medical economics have made them increasingly vulnerable to being named in litigation, according to Susan B. Fink, RN, JD, an attorney with Koskoff, Koskoff & Bieder, PC, of Bridgeport, Conn.

COLUMBUS, Ohio-Many aspects of cancer patient care can be improved or enhanced with the use of music therapy, said Deforia Lane, PhD, resident director of music therapy, University Hospitals of Cleveland-Ireland Cancer Center/Rainbow Babies & Children’s Hospital, and assistant clinical professor of medicine, Case Western Reserve University. Dr. Lane, a board-certified music therapist, spoke at a conference on cancer survivorship sponsored by the Ohio State University’s James Cancer Center and Solove Research Institute.

ORLANDO-The new frontiers in colorectal cancer include multimodality treatment used preoperatively and a new group of oral fluoropyramidine drugs, according to presentations at the Society of Surgical Oncology’s 52nd Annual Cancer Symposium.

COLUMBUS, Ohio-“Fatigue in the cancer patient has multiple causes and must be treated with a variety of strategies,” said Lois Almadrones, MSN, clinical research associate at Memorial Sloan-Kettering Cancer Center.

NEW YORK-In recent years, the practicing anesthesiologist has become more involved in the management of pain and has to be aware of the increasing number of treatments available, said Carol A. Warfield, MD, chief, Division of Pain Services, Beth Israel Deaconess Hospital, Boston.

ALEXANDRIA, Virginia-Drinking grapefruit juice with certain medications, including at least one widely used in cancer treatment, may inhibit their absorption, according to an in vitro study in the April 1999 issue of Pharmaceutical Research, a publication of the American Association of Pharmaceutical Scientists (AAPS).

ORLANDO-Both dye and radioactive tracer are required for finding sentinel lymph nodes most accurately in patients with operable breast cancer, but small intradermal injections of the tracer can be used instead of intraparenchymal tracer injections, researchers from Memorial Sloan-Kettering Cancer Center reported at the Society of Surgical Oncology’s Annual Cancer Symposium.

FORT LAUDERDALE, Fla-Before talking about the various “patients’ bill of rights” legislation before the US Congress, Harry D. Holmes, PhD, played the theme from the movie Back to the Future. “That’s what it seems like in managed care reform, since all of these bills were filed last year and here they are again, both in the House and the Senate.”

WASHINGTON-Overall cancer incidence and mortality have continued to decline in the United States, but incidences of some cancers continue to rise, and significant differences in both incidence and mortality persist among different racial and ethnic groups.

The American Society of ClinicalOncology recently urged Congress to pass the Medicare Cancer Clinical Trials Coverage

WASHINGTON-During the past 16 years, researchers have developed data that suggest cannabinoid-based drugs may be effective for a variety of medical uses, including pain relief, antiemesis, and appetite stimulation in cancer patients, an Institute of Medicine (IOM) committee has concluded. It warned, however, that such medical uses carry some risks, particularly the harmful effects of smoking marijuana, which it discouraged as a means of delivering medications.

Discovery of a marker that allows tracking of thymus function also shows how the adult immune system might repair itself after being damaged by the human immunodeficiency virus (HIV), UT Southwestern Medical Center at Dallas scientists report

ROCKVILLE, Md-Two cancer-related topics are among four new evaluations the Agency for Health Care Policy and Research (AHCPR) has asked the U.S. Preventive Services Task Force to make. The task force is an independent panel of preventive health experts that evaluates the effectiveness of a wide range of clinical preventive services.

BETHESDA, Md-The National Cancer Institute (NCI) has earmarked $30 million for use over the next 5 years to support a group of projects that will unite research scientists and community leaders in efforts to address disparities in national cancer rates among minorities and other underserved groups.

For the first time, the American Societyof Clinical Oncology (ASCO) is hosting a virtual meeting in conjunction with its 35th

ALEXANDRIA, Va-“The Health Care Finance Agency’s plan to reimburse for outpatient Medicare cancer treatment according to ambulatory payment classifications (APCs) would have a crippling effect on research and development of new drug therapies and lower the quality of care for present and future cancer patients,” Congressman Gene Green, Representative of the 29th District of Texas in the US House of Representatives, said at the Annual Meeting of the Association of Community Cancer Centers (ACCC).

BETHESDA, Md-The first human trials of the antiangiogenesis drug endostatin will take place at the University of Wisconsin-Madison and the University of Texas M.D. Anderson Cancer Center. The National Cancer Institute (NCI), which will sponsor the phase I trials, said that the studies will begin in late summer or early fall. Protocols for the two studies had not been worked out at the time of the NCI’s announcement.

As a result of a burgeoning science and an intensive educational campaign that began more than a decade ago, oncologists

Champlin et al review a most interesting topic that has emerged recently; namely, the use of nonmyeloablative conditioning regimens to induce immune-mediated graft-vs-leukemia (GVL) effects, or, in a more general sense, graft-vs-tumor (GVT)

We are entering an extraordinary era in the treatment of patients with indolent non-Hodgkin’s lymphomas (NHL). Several decades were devoted to expending resources on comparing combinations and permutations of conventional agents, but with no beneficial impact on survival.